Prolia is not a bisphosphonate. It belongs to a completely different drug class called RANK ligand (RANKL) inhibitors. While both Prolia and bisphosphonates treat osteoporosis by slowing bone loss, they work through distinct mechanisms, stay in your body for very different lengths of time, and come with different considerations when stopping treatment.
How Prolia Works Differently
Bisphosphonates physically bind to bone mineral. They have a strong chemical attraction to the calcium-rich crystals that make up your skeleton, and once absorbed, they get taken up by osteoclasts, the cells responsible for breaking down old bone. Once inside those cells, bisphosphonates essentially poison them, triggering cell death and slowing the rate at which bone is broken down. Because bisphosphonates embed directly into bone tissue, they accumulate over time and have a tissue half-life of roughly 10 years. This means their effects linger long after you stop taking them.
Prolia (denosumab) never touches bone. Instead, it’s a lab-made antibody that floats in your bloodstream and extracellular fluid, where it intercepts a signaling molecule called RANKL. RANKL is the chemical signal your body uses to tell osteoclasts to mature and start resorbing bone. By blocking that signal, Prolia prevents osteoclasts from forming, functioning, or surviving in the first place. Its half-life is less than 30 days, and once it clears your system, its bone-protective effects fade relatively quickly.
Dosing and How It’s Given
Bisphosphonates come in several forms. Some are daily or weekly pills (like alendronate), and one common option is an intravenous infusion given once a year (zoledronic acid). Oral bisphosphonates have strict dosing rules: you typically take them first thing in the morning on an empty stomach, with a full glass of water, and stay upright for at least 30 minutes to avoid irritating your esophagus.
Prolia is a single injection given under the skin once every six months, administered in the upper arm, thigh, or abdomen. There are no dietary restrictions around it, and most people receive it in a clinic or doctor’s office. If you miss a dose, you should get the injection as soon as possible and then reschedule future doses at six-month intervals from that point.
Who Prolia Is Approved For
The FDA has approved Prolia for several specific groups, all defined as being at high risk for fracture (meaning they’ve already had an osteoporotic fracture, have multiple risk factors, or haven’t responded to other treatments):
- Postmenopausal women with osteoporosis
- Men with osteoporosis
- People on long-term steroids (glucocorticoid-induced osteoporosis), specifically those taking the equivalent of 7.5 mg or more of prednisone daily for at least six months
- Men on hormone therapy for prostate cancer (androgen deprivation therapy)
- Women on aromatase inhibitor therapy for breast cancer
Side Effects Compared to Bisphosphonates
In head-to-head comparisons, the overall rate of side effects between Prolia and bisphosphonates is similar. Both can cause back pain, joint pain, and headaches. Both carry rare but serious risks of osteonecrosis of the jaw (where bone in the jaw deteriorates) and atypical femur fractures (unusual breaks in the thighbone). Neither drug appears to carry a significantly higher risk of these complications than the other in clinical trials.
The practical differences show up elsewhere. Oral bisphosphonates can irritate the esophagus and stomach, which is why the dosing instructions are so specific. Prolia, given by injection, avoids that issue entirely. On the other hand, Prolia has a unique and serious concern that bisphosphonates don’t share: rebound bone loss after stopping.
The Rebound Risk When Stopping Prolia
Because bisphosphonates embed in bone and have that decade-long half-life, their protective effect tapers gradually after you stop. Prolia is the opposite. Once it clears your body, bone breakdown can rebound sharply, sometimes exceeding the rate you had before you ever started treatment. Within 18 months of stopping or even delaying a dose, some patients develop multiple vertebral fractures. People who already had a vertebral fracture before treatment are at the highest risk.
This means Prolia is not a drug you can simply stop on your own. If you and your doctor decide to discontinue it, the typical strategy is to transition to a bisphosphonate afterward to maintain bone protection while the effects of Prolia wear off. Missing or delaying an injection can also trigger this rebound, so staying on schedule matters more with Prolia than with most other osteoporosis treatments.
Switching From Bisphosphonates to Prolia
Many people start on a bisphosphonate and later switch to Prolia, either because of side effects, difficulty tolerating the oral medications, or because their bone density hasn’t improved enough. A large randomized trial of postmenopausal women who had taken oral bisphosphonates for at least two years found that switching to Prolia produced significantly greater gains in bone density than switching to intravenous zoledronic acid. At 12 months, those who switched to Prolia gained 3.2% in lumbar spine density compared with 1.1% for zoledronic acid, and similar advantages appeared at the hip and femoral neck.
One reason for this may be that the residual bisphosphonate stored in bone continues working alongside Prolia’s different mechanism, giving a combined effect. Markers of bone turnover also dropped more sharply in the Prolia group, suggesting a more complete suppression of bone breakdown.
Which One Is Right for You
The choice between Prolia and a bisphosphonate depends on your specific situation. Bisphosphonates are often tried first because they’re available as inexpensive generics, have decades of long-term safety data, and don’t carry the same rebound risk when discontinued. Prolia may be a better fit if you can’t tolerate oral bisphosphonates, have kidney problems (bisphosphonates are cleared through the kidneys, while Prolia is not), or need stronger bone density gains than a bisphosphonate has provided.
The commitment level also differs. Because stopping Prolia requires a careful transition plan, starting it is a longer-term decision than starting a bisphosphonate. Both drugs are effective at reducing fractures, but understanding that they belong to entirely different drug classes, with different mechanisms, timelines, and exit strategies, helps you have a more informed conversation about which one fits your life.